Pain after surgery-acute becomes chronic: might there be a silver ROCKet?
The International Association for the Study of Pain (IASP) has promoted 2017 as the Global Year Against Pain After Surgery 1 . Most anaesthetists would understand this to mean that the focus of this campaign is the treatment of acute postsurgical pain. And this is a valid assumption as we see in our daily practice the severity of acute postoperative pain and the need for its treatment, not only to provide humane relief of suffering, but also to improve and speed up postoperative recovery and enable active postoperative rehabilitation. This again will lead to reduced postoperative morbidity and possibly even mortality. The widespread development of anaesthesia-based acute pain services and the routine of providing excellent evidence-based postoperative analgesia in most hospitals has been the response of our profession to this challenge.
However, 'Pain After Surgery' means more; Shipton has put this so well in a paper in this journal: "All chronic pain was once acute…" 2 . The last 20 years have seen an increasing recognition of a continuum of acute to chronic pain and thereby the relevance of chronic postsurgical pain (CPSP). In an initial publication in 1998 Crombie et al reported that 22.5% of over 5,000 patients seen in UK pain clinics attributed the origin of their chronic pain to previous surgery (and another 18.7% to previous injury) 3 . These initial data have triggered a large number of investigations confirming this impression. Overall, multicentre observational studies in Europe and Australia have shown an incidence of CPSP in the range of 12%, of which up to one-third is rated as severe 4, 5 . Looking from the other way around, an epidemiological population study of the Norwegian city of Tromso, found that 6% of previously pain-free participants who had surgery in the last three years described moderate or severe chronic pain subsequently 6 . Overall, these numbers illustrate that CPSP is an underestimated diagnosis with significant implications for the individuals affected (disability, quality of life, mood disturbances) and the health system and society as a whole (healthcare costs, absenteeism, welfare). In this context it is of note, that the IASP has established a task force to advise the World Health Organization on the inclusion of chronic pain for the upcoming 11th revision of the International Classification of Diseases; 'chronic postsurgical and posttraumatic pain' will be one of the new classifications 7 .
Shipton, in the paper quoted above, continues "…but not all acute pain becomes chronic" 2 . Therefore there has been an increasing interest in understanding the risk factors determining the development of CPSP. It has become obvious that the incidence is dependent on the type of surgery; in particular amputations, thoracic, abdominal and joint replacement surgery (knee more than hip) are high risk, but even after inguinal hernia repair chronic pain is regarded as the "most common and serious long-term problem" 8 . One common denominator here is nerve injury, explaining why often CPSP has characteristics of neuropathic pain 9 . There is also a higher risk for female patients (as for most other chronic pain states) 10 . Other risk factors include genetic predisposition and poor conditioned pain modulation. The role of psychosocial risk factors has most likely been underestimated, as it now becomes obvious that psychological vulnerability, in particular catastrophising personality traits, preoperative anxiety, neuroticism and depression predispose to increased rates of CPSP. Chronic preoperative pain is another important risk factor here. Last, not least, the severity of acute postoperative pain predicts the development of CPSP.
The identification of these risk factors has stimulated a growing interest in how to prevent CPSP, in particular in patients at increased risk. Regional anaesthesia techniques may play an important role here as epidural analgesia for thoracotomy and paravertebral analgesia after breast surgery have been shown to have such an effect in a Cochrane review 11 . This notion is also supported by a number of other studies of regional anaesthesia techniques at a lower level of evidence 10 .
This editorial accompanies a paper by Peyton et al in this issue of Anaesthesia and Intensive Care, which describes a pilot for a large randomised controlled trial (RCT) to identify the role of perioperative ketamine as such a preventive approach. Perioperative ketamine infusion had been identified by a Cochrane review as the most promising systemic option here 12 . However, this Cochrane review is based on a limited number of rather small RCTs with a high risk of bias. This risk is illustrated by the lack of an effect shown in the here-published trial, which is significantly underpowered as were all RCTs included in the preceding Cochrane review.
The dangers of meta-analyses of small trials have also become obvious in this setting for the alpha-2-delta modulators gabapentin and pregabalin. An initial metaanalysis in 2012 showed a preventive effect of perioperative gabapentin and pregabalin 13 ; this was withdrawn for pregabalin by the authors in 2013 14 after a letter to the editor suggesting publication bias in the initial publication 15 . A subsequent Cochrane review in 2013 showed no preventive effect for gabapentin, but a limited benefit for pregabalin at three months 12 . Finally, a most recently published metaanalysis showed no preventive effect of pregabalin at all 16 .
This confusion highlights the need for a large RCT to provide a definitive answer to the question of whether perioperative ketamine administration has a clinically relevant effect on prevention of CPSP. If the answer is yes, this will have important implications for us as anaesthetists, as it would give us a tool to address CPSP in the perioperative setting. It is therefore good to hear that the National Health and Medical Research Council has awarded the investigators of the upcoming ROCKet Trial (Reduction of Chronic Postsurgical Pain with Ketamine), under the auspices of the Australian and New Zealand College of Anaesthetists Clinical Trials Network, the largest NHMRC Project Grant for 2017. The grant of $4.8 million will fund the five-year, 4,884 patient, multicentre, double-blind, placebo-controlled, phase 3/4 randomised controlled trial of the effect of up to 72 hours of perioperative ketamine on the risk of development of CPSP 17 . As this is a multicentre trial, the investigators are interested in being contacted by anaesthesia departments who want to participate in the trial.
While we are awaiting the results of this trial, what can we as anaesthetists do to reduce the incidence and severity of CPSP in the interim? As outlined above, using regional anaesthesia techniques may be an option. But as severity of acute postoperative pain is an important risk factor, we have to assume that good evidence-based multimodal postoperative analgesia can have a preventive effect; this has been shown for improving analgesia after joint replacement surgery 18 .
Another approach is to focus more on the subacute phase of up to six weeks after surgery as this is a rather neglected period 19 . Pain in this period is often undertreated, but has been shown to be predictive for the development of CPSP. The concept suggested here is the development of translational pain services, which identify patients at risk and treat them early in a multidisciplinary approach 20, 21 . Such services could become a component of perioperative medicine with important implications 19 .
